Bace2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| BACE2 Protein | |
|---|---|
| Protein Name | Beta-Secretase 2 |
| Gene | BACE2 |
| UniProt ID | Q15120 |
| PDB IDs | 1KR6, 1M4H, 2VY5 |
| Molecular Weight56.5 k | Da |
| Subcellular Localization | Endoplasmic reticulum, Golgi, Cell membrane |
| Protein Family | Aspartyl protease family |
The BACE2 (Beta-Secretase 2) protein is an aspartyl protease that can cleave amyloid precursor protein (APP). It shares 64% homology with BACE1, the major beta-secretase. BACE2 can cleave APP at the beta-secretase site to initiate amyloidogenic processing, but also possesses alpha-secretase-like activity that may generate non-amyloidogenic fragments. The physiological functions of BACE2 are less well characterized than BACE1, but it has been studied in the context of Alzheimer's disease pathogenesis, Down syndrome, and diabetes mellitus. BACE2 represents an alternative therapeutic target for amyloid reduction strategies.
BACE2 is an aspartyl protease that cleaves APP and has been studied as a potential therapeutic target for Alzheimer's disease.
BACE2 is a 518-amino acid type I transmembrane protein with a large extracellular/luminal domain (residues 1-460) containing two aspartyl protease active sites (DTGS at positions 93-96 and DTLG at 289-292), a stalk region, transmembrane domain (461-483), and short cytoplasmic tail (484-518). The active site contains the conserved Asp-Thr/Ser-Gly motif characteristic of aspartyl proteases.
BACE2 cleaves APP at the β-secretase site to initiate amyloidogenic processing, similar to BACE1. However, BACE2 can also cleave within the Aβ domain (β1-β' cleavage) to generate non-amyloidogenic fragments. BACE2 also processes other substrates including the Notch receptor, IL-1R2, and SEZ6. Its physiological functions include roles in pancreatic β-cell function, adipocyte biology, and possibly neuronal development.
BACE2 is overexpressed in AD brain and in Down syndrome (trisomy 21). Its role in AD is complex - while it generates Aβ, its β1-β' cleavage activity may be protective. BACE2 variants are associated with diabetes risk. BACE2 inhibitors have been developed for AD but must be carefully designed to avoid pancreatic toxicity.
BACE2 inhibitors are in development. Unlike BACE1, BACE2 inhibition may have fewer cognitive side effects. However, its physiological functions in pancreas and other tissues raise safety concerns. Dual BACE1/BACE2 inhibitors have been explored. Substrate-specific inhibitors that preserve beneficial activities are being investigated.
BACE2 expression pattern:
The study of Bace2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.